Mavacoxib

Mavacoxib (CAS No.: 170569-88-7) is a selective cyclooxygenase-2 (COX-2) inhibitor belonging to the class of long-acting non-steroidal anti-inflammatory agents, widely utilized as a pharmacological tool for investigating prostaglandin biosynthesis and inflammation-associated signaling pathways. COX-2 is a key inducible enzyme that catalyzes the conversion of arachidonic acid to prostaglandins and is frequently upregulated in inflammatory conditions and various malignancies, making it an important target in studies of tumor biology and inflammatory responses. Mavacoxib has demonstrated activity in cellular models, including cytotoxic effects in osteosarcoma, mammary carcinoma, and bladder cancer cell lines derived from both human and canine origins, where it can induce apoptosis and inhibit cell migration, in some contexts independently of COX-2 expression levels. Its biochemical activity is typically observed in the nanomolar to low micromolar range in vitro, depending on assay conditions and cell type. Due to its prolonged pharmacokinetic profile and selective mechanism, mavacoxib is frequently employed in preclinical studies to dissect COX-2-dependent and -independent pathways, as well as in screening platforms evaluating anti-inflammatory and anti-proliferative agents. Experimental concentrations and dosing regimens vary according to specific study designs and research objectives.